Key facts
- This page summarizes Pivotal bioVenture Partners Fund I, L.P.'s Form 4 filing for Evommune, Inc..
- 12 reported transactions and 9 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2025, 16:46.
Pivotal bioVenture Partners Fund I, L.P. - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- EVMN on NYSE
- Reported as of
- 07 Nov 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2025, 16:46:56 UTC
- Prior SEC filing
- 05 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pivotal bioVenture Partners Fund I, L.P. filed Form 4 for Evommune, Inc. on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 05 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001695076
Primary reporting owner
Pivotal bioVenture Partners Fund I, L.P.
- Relationship
- Director, 10%+ Owner
- Address
- 501 SECOND STREET, SUITE 200, SAN FRANCISCO
- Signature
- /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner
- Signature date
- 12 Nov 2025
CIK 0001752862
Pivotal bioVenture Partners Fund I G.P., L.P.
- Relationship
- Director, 10%+ Owner
- Address
- 501 SECOND STREET, SUITE 200, SAN FRANCISCO
- Signature
- /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., By: Robert Hopfner, Managing Partner
- Signature date
- 12 Nov 2025
CIK 0001752847
Pivotal bioVenture Partners Fund I U.G.P. Ltd
- Relationship
- Director, 10%+ Owner
- Address
- 501 SECOND STREET, SUITE 200, SAN FRANCISCO
- Signature
- /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P. Ltd., By: Robert Hopfner, Managing Partner
- Signature date
- 12 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,441,032
- Change %
- Price
- Shares after
- 1,441,032
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3, F4, F5, F10
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,632,441
- Change %
- Price
- Shares after
- 1,632,441
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3, F4, F6, F8, F9
EVMN
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +294,502
- Change %
- Price
- Shares after
- 294,502
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Footnotes
- F4, F7, F8, F9
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,145,647
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 838,886
- Exercise price
- Footnotes
- F1, F5, F10
EVMN
transaction
Derivative
Series Seed Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -3,572,816
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 419,441
- Exercise price
- Footnotes
- F1, F6, F8, F9
EVMN
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,582,243
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 324,578
- Exercise price
- Footnotes
- F2, F5, F10
EVMN
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,230,283
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 908,821
- Exercise price
- Footnotes
- F2, F6, F8, F9
EVMN
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,895,260
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 240,756
- Exercise price
- Footnotes
- F3, F5, F10
EVMN
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,104,740
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 267,367
- Exercise price
- Footnotes
- F3, F6, F8, F9
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -313,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 36,812
- Exercise price
- Footnotes
- F4, F5, F10
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -313,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 36,812
- Exercise price
- Footnotes
- F4, F6, F8, F9
EVMN
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,508,575
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 07 Nov 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 294,502
- Exercise price
- Footnotes
- F4, F7, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Footnote F2
Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
Footnote F3
Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
Footnote F4
Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
Footnote F5
Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").
Footnote F6
Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").
Footnote F7
Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").
Footnote F8
The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.
Footnote F9
The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
Footnote F10
The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.